Because of its hijacking by many viruses and bacteria in their infection processes, DC-SIGN has already been the focus of intense efforts, as a target for drug design. Indeed, we and others have developed monovalent and multivalent ligands of DC-SIGN and used them as antagonists to block DC-SIGN-mediated infections of HIV, dengue fever and Ebola . In a recent work, we demonstrated that using previously developed polyvalent glycomimetics we were able to block the trans-infection of SARS-CoV-2 mediated by DC-SIGN . This suggested that antagonist glycomimetics could be efficient additions in the tool-box against SARS-CoV-2 spreading.